Advancing research in infectious diseases and vaccine development
Now more than ever, as global pandemics such as COVID-19 and other infectious diseases threaten people’s lives across the globe, demanding a CRO partner with Medical Counter Measures expertise and a track record of delivering relief when and where it’s needed isn’t just important – it’s critical.
Passionately fighting to protect the health of our nation since 1997, Rho has conducted more than 175 infectious disease studies at 300+ sites and over 100,000 patients. With vast infectious disease expertise extending from program strategy through clinical trials and marketing applications, Rho possesses a distinct advantage when navigating the challenges common to this therapeutic area, including those related to safety and labs, at-risk populations, compliance, genotype/phenotype vendors, and retention.
23+ years of industry-leading federal research experience
Through strong and ongoing relationships with the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), Department of Health and Human Services (DHHS), and 1 of only 5 CROs chosen to be in the BARDA Medical Counter Measures (MCM) Clinical Studies Network, Rho continues to be called upon to assist the U.S. Government in the development of drugs, vaccines and diagnostics that help ensure public safety against the threat of pandemics, bioterrorism and emerging diseases.
BARDA MCM studies awarded to Rho, include:
- Phase 2 Panblok® H7 Influenza Vaccine at Three Dose Levels Adjuvanted with AS03 or MF59 Vaccine Trial
- Phase 2 Safety and Immunogenicity of Anthrax Vaccine in Individuals over 65
- Phase 1 Randomized, Three-Way Crossover Study to Assess the Bioavailability and Pharmacokinetics of a Single Dose of Atropine Administered Sublingually in Healthy Adult Volunteers
Conducting research during the 2009 H1N1 pandemic
During the 2009 H1N1 pandemic, the NIH turned to Rho to rapidly develop and coordinate a national, multisite research project to evaluate the immunogenicity and dosing of the H1N1 vaccine in those with asthma. Rho supported the trial from protocol development through publication of study results.
In less than 18 months, the study team went from the initial study area to publication of the primary study results in the Journal of Allergy and Clinical Immunology. Read the case study.
Our Infectious Disease experience includes the following:
- Hepatitis B
- Hepatitis C
- Herpes Zoster
Our Vaccine experience includes the following:
- Influenza (multiple types/strains)
- Yellow Fever
- Genital HSV-2